Navigation Links
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
Date:10/31/2012

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report third quarter 2012 financial results after the NASDAQ Global Select Market closes on Tuesday, November 6, 2012. The company will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) that day to discuss the corporate update and financial results.

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Third Quarter 2012 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, was approved by the US Food and Drug Administration in June 2012, and is under review for regulatory approval in additional jurisdictions. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information about Arena, please visit www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are regis
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  The Pittsburgh Life Sciences Greenhouse (PLSG), the region,s ... one of its portfolio companies, Medrobotics Corporation, has received ... Robotic System in the U.S.  "I ... said John W. Manzetti , president and CEO ... since spinning out of The Robotics Institute at Carnegie ...
(Date:8/4/2015)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at ... in New York . A live webcast ... A replay will be available approximately one hour after the ...
(Date:8/4/2015)... , Aug. 4, 2015  Armada ... of Massachusetts Medical School,s Clinical Pharmacy Services ... regarding clinical protocols and therapy interventions within ... Specialty medication therapy management is ... to ensure optimal patient outcomes are achieved ...
Breaking Medicine Technology:Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3
... June 21, 2010 ReportsandReports announces it Will,Carry Cardiovascular Devices Market ... , , ... http://www.reportsandreports.com/market-reports/netherlands-cardiovascular-de ,vices-market-outlook-to-2016/) , , , ... (Due to the length of these URLs, it may be necessary to copy ...
... AHMEDABAD, India , June 21, 2010 ... healthcare companies has,received Phase I clinical trial permission from the DCGI for ... Centre using a,unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule. ... ...
Cached Medicine Technology:Cardiovascular Devices Market Outlook June Update by ReportsandReports 2Cardiovascular Devices Market Outlook June Update by ReportsandReports 3Cardiovascular Devices Market Outlook June Update by ReportsandReports 4Cardiovascular Devices Market Outlook June Update by ReportsandReports 5Cardiovascular Devices Market Outlook June Update by ReportsandReports 6Cardiovascular Devices Market Outlook June Update by ReportsandReports 7Cardiovascular Devices Market Outlook June Update by ReportsandReports 8Cardiovascular Devices Market Outlook June Update by ReportsandReports 9Cardiovascular Devices Market Outlook June Update by ReportsandReports 10Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 2Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... whose cancer has come back: Retreatment may be a viable option. Surviving Mesothelioma ... it now. , According to surgeons at the University of New South ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and other long-term care facilities, today announced details of the Advanced level of ... and centers. , Providigm’s QAPI Accreditation program , introduced in 2013, is ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... finds the North America IT reseller channel will grow at least 6 percent ... of their 2014 pace and greater than their OEM/vendor partners. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may decline ... driving, says the August 2015 Harvard Health Letter. , "Age and health conditions ... an individual assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated ...
(Date:8/4/2015)... ... August 04, 2015 , ... Updated enrollment data on the top U.S. health ... be accessed at http://www.AISHealth.com . The data is free to all registered users ... tables and charts on the website’s “Data” section include:, , ...
Breaking Medicine News(10 mins):Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2
... in West Virginia to control obesity in children. The public schools ... a large scale. The game // involves a player moving his/her ... screen. Children aged between 10 years and 14 years will be ... ,West Virginia has turned to computer games to make school children ...
... Wall Street Journal studied about the effects of stress on the pregnant ... number of researches is being conducted on stress and people are in ... ,There is an increase in the number of pregnant women approaching ... ,Hence there is a need to include new ...
... out to be negative for the presence of Japanese ... the health minister Datuk Dr Chua Soi Lek. The ... ,The victim, Norhayati Awang is currently being ... Perempuan Zainab II. According to official reports, she is ...
... by Australian researchers could pave way for an improvement in ... of lung cancer with a high mortality rate. The promising ... definitive diagnosis of lung cancer. ,The study participants were ... rate for these patients was projected to be less than ...
... Food and Drug Administration (FDA) against the seafood processing ... // This will effectively stop the company from ... fish is reported to be contaminated, as a result ... ,The inspections conducted by the FDA in 2004 ...
... Madras Institute of Trauma, more familiarly known as MIOT ... system of a city in Germany, aimed at sharing ... ,MIOT signed a memorandum of understanding ... Stuttgart's public healthcare system is entering into such a ...
Cached Medicine News:Health News:New Treatment Offers Hope For Lung Cancer Patients 2
... The Ray TFC Unite Device is the ... The Ray TFC Unite device features the same ... contact offered by fenestrations is paramount in the ... the Ray TFC Unite system promotes load sharing ...
... The INTER FIX and ... Devices are designed to maximize ... of the implant. Both the ... RP Threaded Fusion devices combine ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
Medicine Products: